METTL14在卵巢上皮性癌组织中的表达及对A2780、SKOV3细胞增殖、侵袭和迁移的影响  

Expression of METTL14 in epithelial ovarian cancer and the effect on cell proliferation,invasion and migration of A2780 and SKOV3 cells

作　　者：韦有生 姚德生[1] 李力[1] 卢艳[1] 杨欣梅 张汶歌 Wei Yousheng;Yao Desheng;Li Li;Lu Yan;Yang Xinmei;Zhang Wenge(Department of Gynecologic Oncology,Guangxi Medical University Cancer Hospital,Nanning 530021,China)

机构地区：[1]广西医科大学附属肿瘤医院妇瘤科,南宁530021

出　　处：《中华妇产科杂志》2022年第1期46-56,共11页Chinese Journal of Obstetrics and Gynecology

基　　金：广西医科大学附属肿瘤医院青年科研基金(2021-03)。

摘　　要：目的研究甲基转移酶样蛋白14(METTL14)在卵巢上皮性癌(卵巢癌)组织中的表达及其临床意义,探讨上调和下调METTL14表达对卵巢癌细胞系A2780、SKOV3细胞增殖、侵袭和迁移的影响。方法(1)组织标本检测:选取2019年12月—2020年11月在广西医科大学附属肿瘤医院行手术治疗的20例卵巢癌患者的新鲜癌组织标本,收集同期因子宫肌瘤行子宫及双侧附件切除术的15例患者的新鲜正常卵巢组织标本作为对照,免疫组化法检测卵巢癌与正常卵巢组织中METTL14蛋白表达的差异。另收集2014年1月—2019年10月在广西医科大学附属肿瘤医院行手术治疗的121例卵巢癌患者的癌组织蜡块,免疫组化法检测卵巢癌组织中METTL14蛋白的表达,并分析METTL14蛋白表达与卵巢癌患者临床病理特征及预后的关系。(2)细胞实验:分别使用慢病毒载体、小分子干扰RNA(siRNA)技术,构建上调、下调METTL14表达的卵巢癌A2780、SKOV3细胞系,并采用逆转录(RT)-实时荧光定量PCR(qPCR)技术和蛋白印迹(western blot)法分别验证其METTL14 mRNA和蛋白的表达。后续的细胞实验分为5组,LV-METTL14组(转染慢病毒载体上调METTL14表达)及其对照LV-NC组(转染阴性对照慢病毒空载体),si-METTL14组(转染si-METTL14-2下调METTL14表达)及其对照si-NC组(转染阴性对照siRNA),以及空白组(未转染)。采用液相色谱-串联质谱(LC-MS/MS)法检测各组卵巢癌细胞中N-6甲基腺嘌呤(m6A)修饰水平的变化,分别采用活细胞计数(CCK-8)法、划痕实验以及穿膜(transwell)小室侵袭和迁移实验检测各组卵巢癌细胞增殖、愈合以及侵袭和迁移能力的变化。结果(1)20份卵巢癌组织中METTL14蛋白的免疫组化总评分为(6.2±3.7)分,显著高于15份正常卵巢组织[(3.3±2.5)分;t=-2.64,P=0.012]。121例卵巢癌患者中,METTL14蛋白高表达(免疫组化总评分≥6分)69例(57.0%,69/121),METTL14蛋白低表达(免疫组化总评分<6分)52例(43.0%,52/Objective To study the expression of methyltransferase-like protein 14(METTL14)in epithelial ovarian cancer and its clinical significance,and to explore the effect of METTL14 expression on the proliferation,invasion and migration of ovarian cancer cells.Methods Immunohistochemistry(IHC)was used to detect METTL14 expression in tumor tissue samples,and analyze the relationships among METTL14 expression,clinicopathological factors,and prognosis in ovarian cancer.Lentiviral vectors and small interfering RNA(siRNA)were used to up-regulate and down-regulate the METTL14 expression in ovarian cancer cell lines A2780 and SKOV3,respectively.Liquid chromatography-tandem mass spectrometry(LC-MS/MS)method was used to detect the N6-methyladenosine(m6A)content in ovarian cancer cells.Cell counting kit-8(CCK-8),wound healing assay,and transwell assay were used to examine the function of METTL14 expression in the cells.Results(1)The IHC score of METTL14 protein was 6.2±3.7 in 20 samples of ovarian cancer tissues and 3.3±2.5 in 15 samples of normal ovarian tissues,and the difference was statistically significant(t=-2.64,P=0.012).Among the patients who suffered from ovarian cancer,there were 69 cases with high expression of METTL14 protein(IHC score≥6),accounting for 57.0%(69/121),and the cases with low expression of METTL14 protein(IHC score<6)accounting for 43.0%(52/121).Compared with the patients with low expression of METTL14,the patients with high expression of METTL14 had later stages,higher rates of lymph node metastasis,abdominal metastasis,and more ascite amount.The differences were statistically significant(all P<0.05).The overall survival rate was significantly lower in patients with high METTL14 expression than the low expression(P=0.009).(2)LC-MS/MS data showed that the relative expression of m6A in A2780 and SKOV3 cells in the lentivirus(LV)-METTL14 group were 0.213±0.024 and 0.181±0.018,which were significantly higher than those in the LV-normal control(NC)group(0.109±0.022 and 0.128±0.020;all P<0.05).While t

关 键 词：卵巢肿瘤 甲基转移酶类 腺苷 甲基化 细胞增殖 肿瘤浸润 

分 类 号：R737.31[医药卫生—肿瘤]